Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates von Cockman, Matthew E, Lippl, Kerstin, Tian, Ya-Min, Pegg, Hamish B, Figg, Jnr, William D, Abboud, Martine I, Heilig, Raphael, Fischer, Roman, Myllyharju, Johanna, Schofield, Christopher J, Ratcliffe, Peter J

Volltext

Lutetium-177-PSMA-617: A Vision of the Future von Chandran, Elias, Figg, William D., Madan, Ravi

Volltext

TMPRSS2: Potential Biomarker for COVID‐19 Outcomes von Strope, Jonathan D., PharmD, Cindy H. Chau, Figg, William D.

Volltext

Drug interactions in cancer therapy von Figg, William D, Scripture, Charity D

Volltext

Resistance to second-generation androgen receptor antagonists in prostate cancer von Schmidt, Keith T., Huitema, Alwin D. R., Chau, Cindy H., Figg, William D.

Volltext

Human prolyl hydroxylase domain 2 reacts with O2 and 2-oxoglutarate to enable formation of inactive Fe(III).2OG.hypoxia-inducible-factor α complexes von Fiorini, Giorgia, Marshall, Stephen A., Figg, William D., Myers, William K., Brewitz, Lennart, Schofield, Christopher J.

Volltext

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis von Nduom, Edjah K, Glod, John, Brown, Desmond A, Fagan, Margaret, Dalmage, Mahalia, Heiss, John, Steinberg, Seth M, Peer, Cody, Figg, William D, Jackson, Sadhana

Volltext

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity von Ceribelli, Michele, Tosto, Frances Anne, Zhang, Xiaohu, Melani, Christopher J, Roschewski, Mark, Beck, Erin, Klumpp-Thomas, Carleen, Peer, Cody J, Wilson, Kelli M, Chen, Lu, McKnight, Crystal, Michael, Sam, Itkin, Zina, Shinn, Paul, Figg, Sr, William D, Wilson, Wyndham H, Staudt, Louis M, Thomas, Craig J

Volltext

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment von Schmidt, Keith T., Chau, Cindy H., Price, Douglas K., Figg, William D.

Volltext

Structure-guided optimisation of N -hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α von Corner, Thomas P, Teo, Ryan Z R, Wu, Yue, Salah, Eidarus, Nakashima, Yu, Fiorini, Giorgia, Tumber, Anthony, Brasnett, Amelia, Holt-Martyn, James P, Figg, Jr, William D, Zhang, Xiaojin, Brewitz, Lennart, Schofield, Christopher J

Volltext

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies von Wesevich, Austin, Goldstein, Daniel A., Paydary, Koosha, Peer, Cody J., Figg, William D., Ratain, Mark J.

Volltext

Single whole genome sequencing analysis blazes the trail for precision medicine von Napoli, Giulia C., Chau, Cindy H., Figg, William D.

Volltext

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleuki... von Conlon, Kevin C, Lugli, Enrico, Welles, Hugh C, Rosenberg, Steven A, Fojo, Antonio Tito, Morris, John C, Fleisher, Thomas A, Dubois, Sigrid P, Perera, Liyanage P, Stewart, Donn M, Goldman, Carolyn K, Bryant, Bonita R, Decker, Jean M, Chen, Jing, Worthy, Tat'Yana A, Figg, Sr, William D, Peer, Cody J, Sneller, Michael C, Lane, H Clifford, Yovandich, Jason L, Creekmore, Stephen P, Roederer, Mario, Waldmann, Thomas A

Volltext

Validation of Analytic Methods for Biomarkers Used in Drug Development von Chau, Cindy H, Rixe, Olivier, McLeod, Howard, Figg, William D

Volltext

Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases von Gril, Brunilde, Paranjape, Anurag N., Woditschka, Stephan, Hua, Emily, Dolan, Emma L., Hanson, Jeffrey, Wu, Xiaolin, Kloc, Wojciech, Izycka-Swieszewska, Ewa, Duchnowska, Renata, Pęksa, Rafał, Biernat, Wojciech, Jassem, Jacek, Nayyar, Naema, Brastianos, Priscilla K., Hall, O. Morgan, Peer, Cody J., Figg, William D., Pauly, Gary T., Robinson, Christina, Difilippantonio, Simone, Bialecki, Emilie, Metellus, Philippe, Schneider, Joel P., Steeg, Patricia S.

Volltext

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials W... von SCHER, Howard I, HALABI, Susan, PETRYLAK, Daniel, KANTOFF, Philip, BASCH, Ethan, KELLY, William Kevin, FIGG, William D, SMALL, Eric J, BEER, Tomasz M, WILDING, George, MARTIN, Alison, HUSSAIN, Maha, TANNOCK, Ian, MORRIS, Michael, STERNBERG, Cora N, CARDUCCI, Michael A, EISENBERGER, Mario A, HIGANO, Celestia, BUBLEY, Glenn J, DREICER, Robert

Volltext

Expression of OATP family members in hormone-related cancers: potential markers of progression von Pressler, Heather, Sissung, Tristan M, Venzon, David, Price, Douglas K, Figg, William D

Volltext

In memoriam Michelle A. Rudek (1972–2023) von Baker, Sharyn D., Figg, William D.

Volltext

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma von PIEKARZ, Richard L, FRYE, Robin, REEDER, Craig, JOSKE, David, FIGG, William D, GARDNER, Erin R, STEINBERG, Seth M, JAFFE, Elaine S, STETLER-STEVENSON, Maryalice, LADE, Stephen, FOJO, A. Tito, BATES, Susan E, TURNER, Maria, WRIGHT, John J, ALLEN, Steven L, KIRSCHBAUM, Mark H, ZAIN, Jasmine, PRINCE, H. Miles, LEONARD, John P, GESKIN, Larisa J

Volltext

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy von STEIN, Wilfred D, GULLEY, James L, FOJO, Tito, SCHLOM, Jeff, MADAN, Ravi A, DAHUT, William, FIGG, William D, NING, Yang-Min, ARLEN, Phil M, PRICE, Doug, BATES, Susan E

Volltext